Last reviewed · How we verify
Locally advanced or metastatic ROS1-positive non-small cell lung cancer
Approved treatments
- Augtyro · Bristol
Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Locally advanced or metastatic ROS1-positive non-small cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
- Locally advanced or metastatic ROS1-positive non-small cell lung cancer treatment landscape brief
- Locally advanced or metastatic ROS1-positive non-small cell lung cancer treatment updates RSS
Frequently asked questions about Locally advanced or metastatic ROS1-positive non-small cell lung cancer
What drugs treat Locally advanced or metastatic ROS1-positive non-small cell lung cancer?
Tracked treatments include Augtyro.
What is the treatment for Locally advanced or metastatic ROS1-positive non-small cell lung cancer?
Standard treatment for Locally advanced or metastatic ROS1-positive non-small cell lung cancer includes Augtyro. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Locally advanced or metastatic ROS1-positive non-small cell lung cancer patent cliff · Locally advanced or metastatic ROS1-positive non-small cell lung cancer CI report
- Treatment: Augtyro · Bristol
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing